PHR

Phreesia, Inc. 10-Q Summary: Quarter Ended July 31, 2019

Business Context and Reporting Period

This is a Quarterly Report on Form 10-Q for Phreesia, Inc., covering the three and six months ended July 31, 2019. Phreesia is a provider of SaaS-based solutions for healthcare provider organizations to manage patient intake and process payments, as well as digital patient engagement services for life sciences companies. The reporting period coincides with the Company's Initial Public Offering (IPO), which closed on July 22, 2019, resulting in the conversion of all redeemable preferred stock to common stock.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 24% year-over-year for the quarter and 22% for the six-month period. Subscription and related services revenue grew 34% (quarter) and 30% (six months), while payment processing fees grew 27% (quarter) and 26% (six months).
• Expense Increases: Operating expenses rose significantly due to growth investments and public company costs. General and administrative expenses increased 60% for the quarter and 43% for the six months, driven by accounting fees, stock compensation, and insurance. Research and development expenses increased 48% (quarter) and 43% (six months).
• Liquidity Transformation: Cash and cash equivalents surged from $1.5 million at January 31, 2019, to $100.1 million at July 31, 2019, primarily due to $130.8 million in net proceeds from the IPO.
• Debt Restructuring: The Company refinanced its debt in February 2019 and used IPO proceeds to fully repay its revolving line of credit ($17.7 million) and prior term loans. As of July 31, 2019, the Company had $20.0 million outstanding on a new term loan and $25.0 million available on a new revolving credit facility.

Guidance, Outlook, and Risks

• Outlook: Management expects to continue incurring net losses and negative cash flows for at least the next year as it invests in growth. The Company believes its current cash position and borrowing capacity are sufficient to fund operations for the next 12 months.
• Key Metrics: Average provider clients increased to 1,558 (quarter) and 1,554 (six months). Patient payment volume processed increased 29% year-over-year to $464 million (quarter) and $925 million (six months).
• Material Weakness: The Company identified a material weakness in internal control over financial reporting due to insufficient accounting personnel and inappropriate segregation of duties. Remediation plans include hiring additional staff and implementing improved controls.
• Risks: Significant risks include reliance on a limited number of clients (top four clients represented ~16% of revenue for the six months), data privacy and security liabilities (HIPAA compliance), competition from EHR/PM providers, and the uncertainty of the healthcare regulatory environment.

Investor Verification Checklist

• Profitability Path: Verify the timeline and assumptions for achieving GAAP profitability given the widening operating losses despite revenue growth.
• Client Concentration: Assess the impact of potential churn or renegotiation from the top four clients, which comprised a significant portion of revenue.
• Internal Controls: Monitor the progress of remediation efforts regarding the identified material weakness in financial reporting controls.
• Debt Covenants: Review the financial covenants in the new credit facility (revenue levels and liquidity requirements) to ensure compliance.
• Payment Processing Margins: Analyze the sensitivity of payment processing margins to potential increases in interchange fees or changes in card network rules.